Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside for Mild Cognitive Impairment
NCT03482167Phase 2Completed
- Sponsor
- University of Delaware
- Start
- Mar 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide riboside in Mild Cognitive Impairment (MCI), sponsored by University of Delaware. Started Mar 2019; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03482167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482167.